Literature DB >> 19813778

Pancytopenia associated with levetiracetam treatment.

Massimo Gallerani1, Elisa Mari, Benedetta Boari, Rossella Carletti, Anna Marra, Michele Cavallo.   

Abstract

Levetiracetam is a pyrrolidine derivate that is approved for the treatment of seizures. It has a favourable pharmacokinetic profile, no clearly established pharmacological interactions, good tolerability and offers the possibility of rapid treatment. We describe a case of pancytopenia and multiple infections observed in the context of levetiracetam treatment. A 65-year-old woman who underwent surgical removal of a meningioma developed progressive pancytopenia complicated by pneumonia and multiple liver abscesses after starting levetiracetam therapy. Bone marrow aspiration and biopsy confirmed the diagnosis. A gradual spontaneous recovery of normal haematopoiesis followed discontinuation of levetiracetam.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19813778     DOI: 10.2165/11319450-000000000-00000

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  10 in total

1.  Levetiracetam-induced thrombocytopenia.

Authors:  Elin Kimland; Bo Höjeberg; Mia von Euler
Journal:  Epilepsia       Date:  2004-07       Impact factor: 5.864

2.  [Leukopenia as side effect of paroxetine].

Authors:  L J Irastorza Eguskiza
Journal:  Actas Esp Psiquiatr       Date:  2004 Sep-Oct       Impact factor: 1.196

3.  Levetiracetam-induced pancytopenia.

Authors:  Bouraoui Elouni; Chaker Ben Salem; Michel Biour
Journal:  Ann Pharmacother       Date:  2009-05       Impact factor: 3.154

4.  Levetiracetam: a long-term follow-up study of efficacy and safety.

Authors:  J Bauer; E Ben-Menachem; G Krämer; W Fryze; S Da Silva; D G A Kasteleijn-Nolst Trenité
Journal:  Acta Neurol Scand       Date:  2006-09       Impact factor: 3.209

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

6.  Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial.

Authors:  Tracy A Glauser; John M Pellock; E Martina Bebin; Nathan B Fountain; Frank J Ritter; Christof M Jensen; W Donald Shields
Journal:  Epilepsia       Date:  2002-05       Impact factor: 5.864

Review 7.  The safety of levetiracetam.

Authors:  Deepa Sirsi; Joseph E Safdieh
Journal:  Expert Opin Drug Saf       Date:  2007-05       Impact factor: 4.250

8.  Thrombocytopenia during levetiracetam therapy.

Authors:  A Meschede; U Runge; M Sabolek
Journal:  Epilepsy Res       Date:  2008-07       Impact factor: 3.045

Review 9.  Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug.

Authors:  Tim De Smedt; Robrecht Raedt; Kristl Vonck; Paul Boon
Journal:  CNS Drug Rev       Date:  2007

10.  Levetiracetam and bleeding disorders.

Authors:  Paul Boon; Réginald Hulhoven; Fritz Offner
Journal:  Acta Neurol Belg       Date:  2007-12       Impact factor: 2.396

  10 in total
  10 in total

1.  Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy.

Authors:  Marta Simó; Roser Velasco; Francesc Graus; Eugenia Verger; Miguel Gil; Estela Pineda; Jaume Blasco; Jordi Bruna
Journal:  J Neurooncol       Date:  2012-03-10       Impact factor: 4.130

2.  Pancytopenia associated with levetiracetam in an epileptic woman.

Authors:  Rafael García Carretero; Marta Romero Brugera; Monica Olid-Velilla; Inmaculada Salamanca-Ramirez
Journal:  BMJ Case Rep       Date:  2016-12-07

Review 3.  Anticonvulsant drugs and hematological disease.

Authors:  A Verrotti; A Scaparrotta; S Grosso; F Chiarelli; G Coppola
Journal:  Neurol Sci       Date:  2014-03-12       Impact factor: 3.307

4.  Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study.

Authors:  Alexander Tinchon; Stefan Oberndorfer; Christine Marosi; Andreas Gleiss; Angelika Geroldinger; Cornelia Sax; Camillo Sherif; Walter Moser; Wolfgang Grisold
Journal:  J Neurol       Date:  2014-10-31       Impact factor: 4.849

5.  Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme.

Authors:  Felipe Batalini; Matthew R Kaufmann; Gabriel Francisco Aleixo; Reed Drews
Journal:  BMJ Case Rep       Date:  2019-06-29

6.  Delayed Recognition of Levetiracetam-induced Pancytopenia.

Authors:  Mohammad Ammad Ud Din; Syed Ather Hussain; Amy Bodrog
Journal:  Eur J Case Rep Intern Med       Date:  2021-03-30

7.  B cell aplasia and hypogammaglobulinemia associated with levetiracetam.

Authors:  Hulya Ozdemir; Sua Sumer; Hakan Karabagli; Gokhan Akdemir; A Zafer Caliskaner; Hasibe Artac
Journal:  Ann Saudi Med       Date:  2018-01-09       Impact factor: 1.526

8.  Levetiracetam for epilepsy: an evidence map of efficacy, safety and economic profiles.

Authors:  Zhan-Miao Yi; Cheng Wen; Ting Cai; Lu Xu; Xu-Li Zhong; Si-Yan Zhan; Suo-Di Zhai
Journal:  Neuropsychiatr Dis Treat       Date:  2018-12-17       Impact factor: 2.570

9.  Multifocal myoclonus as a presentation of levetiracetam toxicity.

Authors:  Mei Bou Nasif; Shweta Varade; Mohamad Z Koubeissi
Journal:  Clin Neurophysiol Pract       Date:  2021-11-07

10.  Levetiracetam-induced pancytopenia.

Authors:  Talal Alzahrani; Dana Kay; Saeed A Alqahtani; Yamane Makke; Linda Lesky; Mohamad Z Koubeissi
Journal:  Epilepsy Behav Case Rep       Date:  2015-07-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.